| AASLD

Home

RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL

Read more about RELATIONSHIP OF NON-INVASIVE MEASURES WITH HISTOLOGICAL RESPONSE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS: 52-WEEK DATA FROM THE PHASE 3 MAESTRO-NASH TRIAL

<div>Background: MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis. 966 patients with biopsy-confirmed NASH were randomized 1:1:1 to resmetirom 80mg, resmetirom 100mg, or placebo administered once daily. Histologic endpoints were assessed after 52 weeks.

PNPLA3 GENOTYPES ARE SIGNIFICANTLY ASSOCIATED WITH LIVER-RELATED OUTCOMES IN INDIVIDUALS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Read more about PNPLA3 GENOTYPES ARE SIGNIFICANTLY ASSOCIATED WITH LIVER-RELATED OUTCOMES IN INDIVIDUALS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

<div>Background: The effect of PNPLA3 rs738409 I148M variant (G allele) on the clinical course of adults with biopsy-proven nonalcoholic fatty liver disease (NAFLD) has not been prospectively investigated. We examined (1) the association between PNPLA3 G allele and clinical outcomes and (2) how relationships among PNPLA3 G allele, age, and type 2 diabetes mellitus (T2DM) impact clinical outcomes in patients with biopsy-proven NAFLD.

MICROBIAL MONOTHERAPY WITH LEUCONOSTOC SP. LB-P8 IMPROVES INFLAMMATION AND FIBROSIS IN MOUSE MODELS OF PRIMARY SCLEROSING CHOLANGITIS.

Read more about MICROBIAL MONOTHERAPY WITH LEUCONOSTOC SP. LB-P8 IMPROVES INFLAMMATION AND FIBROSIS IN MOUSE MODELS OF PRIMARY SCLEROSING CHOLANGITIS.

<div>Background: PSC is an archetypical example of a disease with an impaired gut-liver axis and PSC patients with or without inflammatory bowel disease exhibit enteric microbial dysbiosis. Gut microbiota produce diverse metabolic products but how microbes influence PSC disease progression is unclear. By screening bacterial species (sp.) in a transwell gut-liver axis model, we identified novel Leuconostoc sp. (LB-P8) that may have anti-fibrotic properties via inhibition of TGF-β/SMAD signaling.

ALBUMIN IS INTERNALIZED BY PRIMARY MONOCYTES USING CLATHRIN-INDEPENDENT ENDOCYTOSIS WHICH IS REQUIRED FOR ITS ANTI-INFLAMMATORY EFFECT.

Read more about ALBUMIN IS INTERNALIZED BY PRIMARY MONOCYTES USING CLATHRIN-INDEPENDENT ENDOCYTOSIS WHICH IS REQUIRED FOR ITS ANTI-INFLAMMATORY EFFECT.

<div>Background: Albumin has been shown to modulate systemic inflammation in patients with decompensated liver cirrhosis receiving infusions of this protein as therapy. Although the anti-inflammatory effect of albumin has been described to be secondary to its internalization into mononuclear leukocytes, the cell type and the mechanism by which albumin is internalized by these immune cells are at present unknown.

ETHANOL-INDUCED REDUCTION IN THE INTESTINAL METHYLATION POTENTIAL PROMOTES TIGHT JUNCTION DISRUPTION: PROTECTION BY BETAINE TREATMENT

Read more about ETHANOL-INDUCED REDUCTION IN THE INTESTINAL METHYLATION POTENTIAL PROMOTES TIGHT JUNCTION DISRUPTION: PROTECTION BY BETAINE TREATMENT

<div>Background: The gut-liver interaction has emerged as a critical component in alcohol-associated liver disease (ALD) pathogenesis. The central mediators are the gut luminal antigens, especially endotoxins that translocate to the liver. This occurs because of (i) compromised gut barrier integrity due to epithelial tight junction (TJ) disruption; and (ii) qualitative/quantitative gut microbiota changes and increased production of pathogenic antigens.

NOVEL MECHANISMS UNDERLYING GUT LEAKINESS AND SYSTEMIC ENDOTOXEMIA IN PROMOTING LIVER FIBROSIS VIA THE GUT-LIVER AXIS AND THE MECHANISTIC PROTECTION OF MELATONIN

Read more about NOVEL MECHANISMS UNDERLYING GUT LEAKINESS AND SYSTEMIC ENDOTOXEMIA IN PROMOTING LIVER FIBROSIS VIA THE GUT-LIVER AXIS AND THE MECHANISTIC PROTECTION OF MELATONIN

<div>Background: Liver fibrosis is the consequence of chronic liver diseases that can progress to cirrhosis and liver failure. However, the role and mechanism of gut leakiness in liver fibrosis are poorly understood, and there is no FDA-approved drug to treat liver fibrosis.

CILIARY AND CELL STRUCTURE GENE VARIANTS CONTRIBUTE TO THE ETIOPATHOGENESIS OF BILIARY ATRESIA (BA): EXOME AND SNP ARRAY ANALYSIS OF >1700 NORTH AMERICAN CHILDREN WITH BA

Read more about CILIARY AND CELL STRUCTURE GENE VARIANTS CONTRIBUTE TO THE ETIOPATHOGENESIS OF BILIARY ATRESIA (BA): EXOME AND SNP ARRAY ANALYSIS OF >1700 NORTH AMERICAN CHILDREN WITH BA

<div>Background: Biliary atresia (BA) is the principal indication for liver transplantation in children, yet there is little information regarding its underlying etiology. Recent data strongly places BA as a developmental cholangiopathy suggesting that there are gene variant contributions that can be discovered using modern gene sequencing and analytical technologies.

HBV VIRUS-HOST CHIMERA DNA SERVES AS A PERSONALIZED CIRCULATING BIOMARKER FOR RESIDUAL TUMORS AFTER SURGICAL RESECTION OF HEPATOCELLULAR CARCINOMA

Read more about HBV VIRUS-HOST CHIMERA DNA SERVES AS A PERSONALIZED CIRCULATING BIOMARKER FOR RESIDUAL TUMORS AFTER SURGICAL RESECTION OF HEPATOCELLULAR CARCINOMA

<div>Background: Early recurrence of hepatocellular carcinoma (HCC) after surgical resection compromises patient survival. Timely detection of minimal residual tumor is helpful in recurrence monitoring and evaluating treatment strategies. This study examined the feasibility of virus-host chimera DNA (vh-DNA) generated from integration sites of hepatitis B virus (HBV) in the HCC chromosome as a personalized circulating biomarker for residual tumors after surgery.

THREE-DIMENSIONAL MR ELASTOGRAPHY IDENTIFIES PORTAL HYPERTENSION IN CIRRHOSIS: A PROSPECTIVE MULTICENTER STUDY

Read more about THREE-DIMENSIONAL MR ELASTOGRAPHY IDENTIFIES PORTAL HYPERTENSION IN CIRRHOSIS: A PROSPECTIVE MULTICENTER STUDY

<div>Background: To develop a non-invasive multivariate models based on Three-dimensional MR elastography (3D-MRE) to determine portal hypertension (PH), particularly to diagnose clinically significant portal hypertension (CSPH, HVPG>10mmHg) and severe portal hypertension (SPH, HVPG>12mmHg), using HVPG as the gold standard.

TRENDS IN UTILIZATION AND POST-TRANSPLANT OUTCOMES IN COVID-19 POSITIVE DECEASED DONOR LIVER TRANSPLANTATION

Read more about TRENDS IN UTILIZATION AND POST-TRANSPLANT OUTCOMES IN COVID-19 POSITIVE DECEASED DONOR LIVER TRANSPLANTATION

<div>Background: Initial recommendations from scientific societies cautioned against procurement of livers from COVID-19(+) donors. Growing evidence supports the short-term safety of liver transplantation from COVID-19(+) donors. We described usage of liver transplants from COVID-19(+) donors during the COVID-19 pandemic and characterized associated transplant outcomes using data from the United Network for Organ Sharing registry.

Subscribe to